Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600834 · ClinicalTrials.gov registry record
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
A clinical trial, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 172
- Enrollment target
NCT00600834: Completed study, sponsored by Bracco Diagnostics.
NCT00600834 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 172 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600834 has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 172 participants
- Enrollment target
Study Summary
The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease or kidney failure eGFR \<30).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2008-02 |
| Est. Completion | 2013-05 |
What the finished NCT00600834 record still lists
NCT00600834 is an observational study that tracks outcomes without assigning an intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00600834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00600834 about?
NCT00600834 is a clinical study titled "Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease". The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease or kidney failure eGFR \<30).
What is the current status of trial NCT00600834?
This trial is currently completed. The enrollment target is 172 participants. The study started on 2008-02. Estimated completion is 2013-05.
Who is sponsoring clinical trial NCT00600834?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia